European Pharmaceutical Review

NOVEMBER 22, 2022

The US Food and Drug Administration ( FDA ) has accepted priority review of AbbVie’s Biologics License Application of epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody (BsAb), for adults with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

FDA 83

FDA Food and Drug Administration Safety Food 83

Pharmaceutical Technology

MAY 26, 2023

After earning multimillion dollar revenues while being an authorised preferred treatment for Covid-19, the US Food and Drug Administration (FDA) has granted a full approval to Pfizer’s oral antiviral Paxlovid (nirmatrelvir + ritonavir). In response to the approval news, some pointed concerns about long-term safety.

Food and Drug Administration 59

Food and Drug Administration FDA Side effects Safety 59

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has accepted Satsuma Pharmaceuticals’ 505(b)(2) new drug application (NDA) for STS101 for acute treatment of migraine, for review. The company’s NDA was supported mainly by the data obtained from the Phase I clinical trial completed in June 2021, and the Phase III ASCEND trial.

Food and Drug Administration 59

Food and Drug Administration FDA Prescription Food 59

Pharmaceutical Technology

APRIL 18, 2023

The US Food and Drug Administration (FDA) has granted approval for the expanded indication of AbbVie ’s Qulipta (atogepant) as a preventive treatment for chronic migraines in adult patients. Qulipta received the FDA’s approval to treat episodic migraine in adults in September 2021.

Food and Drug Administration 52

Food and Drug Administration FDA Food Safety 52

Pharmaceutical Technology

JUNE 14, 2023

Ipsen has received US Food and Drug Administration (FDA) approval for Bylvay (odevixibat) to treat patients aged 12 months and above with cholestatic pruritus caused by Alagille syndrome (ALGS).

Food and Drug Administration 52

Food and Drug Administration FDA Transportation Prescription 52

Pharma Leaders

MAY 8, 2023

The Food and Drug Administration (FDA) has successfully inspected Nexus Pharmaceuticals’ pharmaceutical manufacturing facility located in Pleasant Prairie, Wisconsin, US. Nexus Pharmaceuticals stated that the regulatory approval process validates facilities’ compliance with stringent quality and safety standards.

Manufacturing 52

Manufacturing Food and Drug Administration FDA Pharmaceutical manufacturing 52

European Pharmaceutical Review

FEBRUARY 2, 2024

Biogen’s decision A strategic review of the company’s R&D work evaluated the time and investment required for the post-marketing confirmatory ENVISION study and the likely advancements in the field by the time of potential ADUHELM FDA traditional approval, Biogen explained.

Food and Drug Administration 73

Food and Drug Administration FDA Food Marketing 73

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Consequently, the US Food and Drug Administration (FDA) and other agencies are keen to see “accelerated development” programmes in areas where there is a significant unmet clinical need. He is currently a CMC consultant with an interest in impurities and safety‑based limits. billion, and rising.

Food and Drug Administration 74

Food and Drug Administration FDA Safety Food 74

European Pharmaceutical Review

OCTOBER 25, 2023

The document by the Medicines and Healthcare products Regulatory Agency (MHRA), US Food and Drug Administration (FDA) and Health Canada, contains key guidance on predetermined change control plans (PCCPs) for MLMDs. The device may be reassessed to ensure the performance and safety of the device is negatively impacted.

Medical 88

Medical Food and Drug Administration Manufacturing Safety 88

European Pharmaceutical Review

APRIL 25, 2023

Granted full national licensure by the country’s Food and Drugs Authority (FDA Ghana), it is authorised for children aged 5 to 36 months. Recent data from the ongoing Phase III trial in that enrolled 4,800 children, also show high levels of efficacy and a reassuring safety profile.

Manufacturing 105

Manufacturing Safety Food Medicine 105

pharmaphorum

OCTOBER 27, 2022

The FDA has accepted for review Seres Therapeutics’ Biologics License Application (BLA) for SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent Clostridium difficile infection (rCDI). If approved, SER-109 would be the first-ever FDA-approved oral microbiome therapeutic. Now at $6.79

FDA 44

FDA Prescription Food Medical 44

Pharmaceutical Technology

APRIL 14, 2023

Ghana’s Food and Drug Authority (FDA) has approved R21/Matrix-M malaria vaccine in children aged 5 to 36 months, marking the first regulatory clearance for the University of Oxford-developed vaccine in any country in the world. Children between the ages of five and 36 months are at highest risk of death from malaria.

Manufacturing 111

Manufacturing FDA Food Safety 111

Pharmaceutical Technology

APRIL 3, 2023

Treatment is then conducted as a clinical trial by the National Cancer Center Hospital to confirm its safety and efficacy. Developed using Epizyme’s proprietary product platform, tazemetostat received approval to treat relapsed or refractory EZH2 gene mutation-positive follicular lymphoma in Japan in 2021.

Insurance 98

Insurance Government Safety Patients 98

pharmaphorum

AUGUST 19, 2022

The endorsement of the drug’s efficacy and safety comes at a good time for the Swedish biotech, just a month before the drug, known as Pepaxto in the US, will have its safety reviewed by an FDA advisory committee after being withdrawn from sale there last year.

FDA 52

FDA Safety Sales Marketing 52

Pharmaceutical Technology

MAY 9, 2023

The US Food and Drug Administration (FDA) has granted Vedanta Biosciences’ oral microbiome treatment VE303 a fast track designation for the treatment of recurrent Clostridioides difficile (C.diff) infection, as the company plans to start a Phase III trial later this year, based on a May 8 announcement. diff infections every year in the US.

Food and Drug Administration 52

Food and Drug Administration FDA Food Safety 52

European Pharmaceutical Review

JULY 28, 2023

The SKYLARK findings support the potential for US Food and Drug Administration (FDA) approval of the first oral, at-home, neuroactive steroid therapy to treat postpartum depression. Phase III ROBIN trial In 2021, Phase III results of the ROBIN clinical trial were published in the Journal of the American Medical Association (JAMA) Psychiatry.

Food and Drug Administration 85

Food and Drug Administration Food Safety FDA 85

European Pharmaceutical Review

DECEMBER 7, 2022

The Commission on Human Medicines (CHM), which endorsed the authorisation, advises ministers on the safety, efficacy and quality of medicinal products. In November 2021, the US Food and Drug Administration (FDA) authorised the emergency use of COVID-19 vaccine Comirnaty ® in children aged five to 11 years.

Food and Drug Administration 81

Food and Drug Administration Patients Side effects Medicine 81

pharmaphorum

JANUARY 27, 2023

The decision comes after Ipsen was forced to withdraw its marketing application for palovarotene in the US in 2021, which delayed regulatory filings elsewhere, although the French pharma company has picked up an approval for the drug in Canada, where it is sold as Sohonos.

FDA 92

FDA Marketing Medicine Prospecting 92

European Pharmaceutical Review

JUNE 16, 2023

Pharmacovigilance and machine learning Applications of ML include analysing social media posts for safety insights, extracting information from clinical narratives in electronic health records (EHRs) and integrating data sources with multiple analytical approaches to provide richer insights. Bate et al.

Safety 87

Safety Electronics Medicine Government 87

Legacy MEDSearch

DECEMBER 6, 2022

With ActivSight, surgeons can access critical intraoperative visual data as augmented reality overlays, helping to increase surgical outcomes and patient safety. “As We believe ActivSight will be a game-changer in the operating room by revolutionizing surgical vision and, ultimately, improving surgical care and patient safety.

Food and Drug Administration 98

Food and Drug Administration Safety Recruitment Medical 98

European Pharmaceutical Review

MARCH 4, 2024

Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 The emergency use approval from the FDA of lipid nanoparticle- (LNP-) based mRNA vaccines during the COVID-19 pandemic attested the significance of LNPs.

Food and Drug Administration 86

Food and Drug Administration Transportation FDA Medical 86

European Pharmaceutical Review

NOVEMBER 8, 2022

There are also several pending bills that seek to lower drug costs by means other than price regulations, including: 1) deterring the delay in FDA approval of drug applications caused by sham ‘Citizen Petitions’. Citizen Petitions before the FDA. 562 would permit the FDA to deny the petition if either of these factors were satisfied.

Food and Drug Administration 52

Food and Drug Administration Pharma Prescription Manufacturing 52

European Pharmaceutical Review

AUGUST 28, 2023

Potential of inclisiran for lowering LDL-C These findings “reconfirm and extend prior observations about the safety profile and efficacy of inclisiran for people with ASCVD and those at risk of cardiovascular disease, in whom cholesterol levels are not adequately controlled,” Dr Ray explained.

Food and Drug Administration 96

Food and Drug Administration Consulting Patients Food 96

European Pharmaceutical Review

DECEMBER 21, 2022

Despite the tidal wave of renewed interest in psychedelic therapies, there is still much to be learned about them, including their precise mechanisms of action, their long- and short-term safety profiles, the durability of their effect, and their adverse effects—which can be severe. Authorisation under exceptional circumstances.

Food and Drug Administration 105

Food and Drug Administration Medicine Food Government 105

European Pharmaceutical Review

OCTOBER 31, 2022

Additionally, Danish biotech Genmab has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for epcoritamab for adult patients with R/R large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. The submissions are supported by Phase II trial data.

Food and Drug Administration 83

Food and Drug Administration Medicine Food Safety 83

pharmaphorum

JANUARY 23, 2023

” It was modified again in the middle of 2021. Janssen opted not to continue with the first two integrin targets at the end of 2021, due to “a lack of target validation in the specific disease of Janssen’s interest,” and has now dropped the third, bringing the partnership to an early end.

Safety 52

Safety FDA Pharma 52

pharmaphorum

OCTOBER 27, 2022

It’s a disappointing outcome for a programme that GSK said in 2021 could potentially generate £1 to £2 billion in peak sales because of the serious unmet need in RA patients. The non-dialysis segment is, however, a key part of GSK’s hopes of £500 million to £1 billion in peak sales for the drug.

Side effects 81

Side effects FDA Patients Sales 81

Pharmaceutical Technology

DECEMBER 5, 2022

Notably, Lupkynis is the first oral therapy approved by the US Food and Drug Administration (FDA) and EC for the treatment of active LN. Overall, Aurinia’s Lupkynis is expected to face tough competition from Benlysta in LN, which received FDA approval in December 2020 and EMA approval in May 2021.

Food and Drug Administration 59

Food and Drug Administration Physicians Competition FDA 59

pharmaphorum

DECEMBER 14, 2022

Sodium oxybate — which in the late 1980s was marketed to bodybuilders and then became known as GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDA approval in 2002. In 2020, the FDA-approved indication was expanded to include those patients who suffer from cataplexy. Monopoly money.

Competition 96

Competition FDA Pharmaceutical Marketing 96

European Pharmaceutical Review

AUGUST 31, 2023

Overcoming challenges in patient safety, manufacturing and supply of radiopharmaceuticals As clinical trials progress and the first results are published, companies’ best candidates will emerge in the next five years. Hospital staff must also be protected from radiation while handling the agent.

Food and Drug Administration 75

Food and Drug Administration Manufacturing Safety Transportation 75

European Pharmaceutical Review

MAY 4, 2023

Data announced at the European Lung Cancer Congress (ELCC) earlier this month revealed the long-term efficacy and safety of RYBREVANT ® (amivantamab) in patients with post-platinum EGFR Ex20ins-mutated advanced non-small cell lung cancer (NSCLC). Personalized medicine at FDA. What are the current trends in antibody therapeutics?

Food and Drug Administration 89

Food and Drug Administration Safety Medicine Patients 89

pharmaphorum

JANUARY 5, 2023

The deal centres on reSET and reSET-O, Pear’s cognitive behavioural therapy (CBT) based programmes, for people living with substance and opioid use disorders, respectively, which have been approved by the FDA as an adjunct to outpatient treatment.

Prescription 52

Prescription Specialization FDA Networking 52

Pharmaceutical Technology

NOVEMBER 14, 2022

Such developments, including a 2021 approval of AstraZeneca’s Saphnelo (anifrolumab) , prompted The Lancet Rheumatology to posit that 2022 could be a “banner year” for the condition. The CAR-T therapies for conditions like lupus continue to look promising, but their safety is a concern, says Gilkeson. MSCs and CAR-Ts for lupus.

Side effects 144

Side effects Patients Manufacturing Safety 144

Pharmaceutical Technology

JULY 8, 2022

In December 2014, Amgen’s landmark FDA approval saw Blincyto (blinatumomab) approved for relapsed/refractory (R/R) B-cell progenitor acute lymphoblastic leukaemia (B-ALL), at the time being the only marketed BiTE. months vs. 4.0

Safety 59

Safety Sales Marketing Patients 59

pharmaphorum

DECEMBER 22, 2022

Prediction 1: the FDA will become more directive and collaborative on guidelines for DCTs. The risk of not having these discussions is to conduct expensive trials only to discover too late that they were measuring the wrong endpoint, in the wrong way, or with a tool or technology the FDA does not accept.

FDA 85

FDA Patients Electronics Medical 85

pharmaphorum

SEPTEMBER 12, 2022

CodeBreak-200 will nevertheless likely serve as a confirmatory study for the approval of Lumakras (sotorasib) in this heavily pretreated patient population, which was granted by the FDA in May 2021.

Side effects 52

Side effects FDA Patients Safety 52

European Pharmaceutical Review

JUNE 27, 2023

Hervé Affagard (HA): Developing microbiome therapeutics as well as every other new therapeutic modality comes with several challenges that need to be addressed carefully to ensure patient safety and maximise the potential benefits of these treatments. et al, Science, 2021 ; Baruch EN et al. Science, 2021. cited 2023June].

Food and Drug Administration 96

Food and Drug Administration Manufacturing Medicine Pharma 96